Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2992-3004

  Nakatani, Shingo ^a   Hidaka, Koushi ^a   Ami, Ei'Ichi ^a   Nakahara, Koichiro ^b   Sato, Akihiko ^b   Nguyen, Jeffrey Tri ^a   Hamada, Yoshio ^a   Hori, Yasuko ^a   Ohnishi, Nobuyuki ^a   Nagai, Akinori ^a   Kimura, Tooru ^a   Hayashi, Yoshio ^a   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (TERT BUTOXYCARBONYL)AMINO 3 (4 CLOROPHENYLSULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (4 METHOXYBENZYLSULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (4 METHYLBENZYLSULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (4 METHYLBENZYLTHIO)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (BENZYLSULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (NAPHTHALENE 1 YL SULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (NAPHTHALENE 2 YL SULFONYL)PROPANOIC ACID; 2 (TERT BUTOXYCARBONYL)AMINO 3 (QUINOLINE 2 YL SULFONYL)PROPANOIC ACID; CYSTEINE; DEXTRO AMINO ACID; N (2 METHYLBENZYL) 3 [2 HYDROXY 3 (2 METHYLSULFONYLAMINO 4 PHENYLBUTANOYL)AMINO 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [2 HYDROXY 3 (3 (4 METHOXYBENZYLTHIO) 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [2 HYDROXY 3 (3 4 METHYLBENZYLTHIO) 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [2 HYDROXY 3 (3 QUINOLINE 2 YL THIO) 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (4 METHYLBENZYLSULFONYL)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (4 METHYLBENZYLTHIO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (BENZYLOXY)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (BENZYLSULFONYL)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (BENZYLTHIO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 3 (QUINOLINE 2 YL THIO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (2 ACETYLAMINO 4 PHENYLBUTANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (3 BENZYLOXY 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (3 BENZYLSULFONYL 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N (2 METHYLBENZYL) 3 [3 (3 BENZYLTHIO 2 (METHYLSULFONYLAMINO)PROPANOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; NELFINAVIR; OROSOMUCOID; PROTEINASE INHIBITOR; SERINE DERIVATIVE; TIMONACIC DERIVATIVE; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

AMINO ACIDS; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MUTATION; PHENYLBUTYRATES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 43949118096     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701555p     Document Type: Article

References (36)

1. UNAIDS and WHO AIDS Epidemic Update: December 2006; UNAIDS: Geneva, 2006.
2. AIDS Info: A Service of the U.S. Department of Health and Human Services; http://aidsinfo.nih.gov/ (accessed August 27, 2007).
3. (a) Wlodawer, A.; Miller, M.; Jaskilolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L.; Clawson, L.; Schneider, J.; Kent, S. B. H. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989, 245, 616-621.
4. (b) Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C.-T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337, 615-620.
5. (c) Lappoto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheld, K. G.; Hobart, P. M. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989, 342, 299-302.
6. Johnson, V. A.; Brun-Vézinet, F.; Clotet, B.; Conway, B.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J.; Telenti, A.; Richman, D. Update of the drug resistance mutations in HIV-1: 2005. Top. HIV Med. 2005, 13, 51-57.
7. Thaisrivongs, S.; Strohbach, J. W. Structure-based discovery of Tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999, 51, 51-58.
8. (a) Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Walters, D. E.; Krishnan, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere. Bioorg. Med. Chem. Lett. 1998, 8, 687-690.
9. (b) Surleraux, D. L. N. G.; Tahri, A.; Verschueren, W. G.; Pille, G. M. E.; de Kock, H. A.; Jonckers, T. H. M.; Peeters, A.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M.-P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. T. P. Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor. J. Med. Chem. 2005, 48, 1813-1822.
10. Velazquez-Campoy, A.; Vega, S.; Freire, E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002, 41, 8613-8619.
11. Clemente, J. C.; Coman, R. M.; Thiaville, M. M.; Janka, L. K.; Jeung, J. A.; Nukoolkarn, S.; Govindasamy, L.; Agbandje-McKenna, M.; McKenna, R.; Leelamanit, W.; Goodenow, M. M.; Dunn, B. M. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to Atazanavir. Biochemistry 2006, 45, 5468-5477.
12. Miller, J. F.; Andrews, C. W.; Brieger, M.; Furfine, E. S.; Hale, M. R.; Hanlon, M. H.; Hazen, R. J.; Kaldor, I.; McLean, E. W.; Reynolds, D.; Sammond, D. M.; Spaltenstein, A.; Tung, R.; Turner, E. M.; Xu, R. X.; Sherrill, R. G. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorg. Med. Chem. Lett. 2006, 16, 1788-1794.
13. Amano, M.; Koh, Y.; Das, D.; Li, J.; Leschenko, S.; Wang, Y.-F.; Boross, P. I.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. A novel bis- tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 2007, 51, 2143-2155.
14. (a) Kiso, Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 1996, 40, 235-244.
15. (b) Mimoto, T.; Imai, J.; Kisanuki, S.; Enomoto, H.; Hattori, N.; Akaji, K.; Kiso, Y. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem. Pharm. Bull. 1992, 40, 2251-2253.
16. Mimoto, T.; Hattori, N.; Takaku, H.; Kisanuki, S.; Fukazawa, T.; Terashima, K.; Kato, R.; Nojima, S.; Misawa, S.; Ueno, T.; Imai, J.; Enomoto, H.; Tanaka, S.; Sakikawa, H.; Shintani, M.; Hayashi, H.; Kiso, Y. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere. Chem. Pharm. Bull. 2000, 48, 1310-1326.
17. Kiso, Y. Design and synthesis of a covalently linked HIV-1 protease dimmer analog and peptidomimetic inhibitors. J. Synth. Org. Chem., Jpn. 1998, 56, 896-907.
18. Mimoto, T.; Kato, R.; Takaku, H.; Nojima, S.; Terashima, K.; Misawa, S.; Fukazawa, T.; Ueno, T.; Sato, H.; Shintani, M.; Kiso, Y.; Hayashi, H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 1999, 42, 1789-1802.
19. Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M. F.; Maroun, V.; Nguyen, A.; Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.; Erickson, J.; Mitsuya, H. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8675-8680.
20. Kiso, Y.; Matsumoto, H.; Mizumoto, S.; Kimura, T.; Fujiwara, Y.; Akaji, K. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999, 51, 59-68.
21. Mimoto, T.; Imai, J.; Tanaka, S.; Hattori, N.; Takahashi, O.; Kisanuki, S.; Nagano, Y.; Shintani, M.; Hayashi, H.; Sakikawa, H.; Akaji, K.; Kiso, Y. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. 1991, 39, 2465-2467.
22. Mimoto, T.; Imai, J.; Tanaka, S.; Hattori, N.; Kisanuki, S.; Akaji, K.; Kiso, Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. 1991, 39, 3088-3090.
23. Baldwin, E. T.; Bhat, T. N.; Gulnik, S.; Liu, B.; Topol, I. A.; Kiso, Y.; Mimoto, T.; Mitsuya, H.; Erickson, J. W. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995, 3, 581-590.
24. Wang, Y.-X.; Freedberg, D. I.; Yamazaki, T.; Wingfield, P. T.; Stahl, S. J.; Kaufman, J. D.; Kiso, Y.; Torchia, D. A. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 1996, 35, 9945-9950.
25. Abdel-Rahman, H. M.; Kimura, T.; Hidaka, K.; Kiso, A.; Nezami, A.; Freire, E.; Hayashi, Y.; Kiso, Y. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol. Chem. 2004, 385, 1035-1039.
26. Ami, E.; Nakahara, K.; Sato, A.; Nguyen, J.-T.; Hidaka, K.; Hamada, Y.; Nakatani, S.; Kimura, T.; Hayashi, Y.; Kiso, Y. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties. Bioorg. Med. Chem. Lett. 2007, 17, 4213-4217.
27. Kato, R.; Takahashi, O.; Kiso, Y.; Moriguchi, I.; Hirono, S. Solution structure of HIV-1 protease-allophenylnorstatine derived inhibitor complex obtained from molecular dynamics simulation. Chem. Pharm. Bull. 1994, 42, 176-178.
28. 3 ligands for inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 1994, 4, 1391-1396.
29. Munroe, J. E.; Shepherd, T. A.; Jungheim, L. N.; Hornback, W. J.; Hatch, S. D.; Muesing, M. A.; Wiskerchen, M.; Su, K. S.; Campanale, K. M.; Baxter, A. J.; Colacino, J. M. Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acids. Bioorg. Med. Chem. Lett. 1995, 5, 2897-2902.
30. 3 ligands. J. Med. Chem. 1996, 39, 96-108.
31. Tamamura, H.; Koh, Y.; Ueda, S.; Sasaki, Y.; Yamasaki, T.; Aoki, M.; Maeda, K.; Watai, Y.; Arikuni, H.; Otaka, A.; Mitsuya, H.; Fujii, N. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 Strains. J. Med. Chem. 2003, 46, 1764-1768.
32. Arnord, L. D.; Kalantar, T. H.; Vederas, J. C. Conversation of serine to stereochemically pure β-substituted α-amino acids via β-lactones. J. Am. Chem. Soc. 1985, 107, 7105-7109.
33. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
34. 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. Drug Metab. Dispos. 2002, 30, 859-860.
35. Vega, S.; Kang, L. W.; Velazquez-Campoy, A.; Kiso, Y.; Amzel, L. M.; Freire, E. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins: Struct., Funct. Bioinform. 2004, 55, 594-602.
36. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.